Last reviewed · How we verify
NCT04318639
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
Phase 2, PHASE3 trial testing Donepazil in Alcohol Use Disorder in 15 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | VA Connecticut Healthcare System |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 17 August 2018 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Donepazil
Conditions studied
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
VA Connecticut Healthcare System — full company profile →
Who can join
Adults 21 to 80, any sex, with Alcohol Use Disorder or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label feasibility trial to learn whether the combination of donepezil and cognitive remediation therapy (Donepezil + CRT) may improve neurocognitive functioning and decreasing alcohol use in Veterans with alcohol use disorder who have mild cognitive impairment (AUD-MCI). The study will determine the acceptability and adherence to treatment and preliminary evidence for efficacy. The study will recruit 15 newly recovering Veterans individuals with AUD-MCI for a 13-week, open-label, single-arm pilot study with sobriety and cognitive assessments at baseline and at 13-week follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04318639
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcohol Use Disorder
Currently open trials in the same condition.
- NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
- NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
- NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
Other VA Connecticut Healthcare System trials
Trials by the same sponsor.
- NCT04044534 — Intranasal Insulin for Posttraumatic Stress Disorder · Phase 2 · recruiting
- NCT03329157 — Rebuilding Bridges for Homeless Veterans · NA · withdrawn
- NCT05042102 — Donepezil and Cognitive Training for Alcohol Use Disorder (AUD) · Phase 2 · recruiting
- NCT05093556 — Interactive CBT for Headache And Relaxation Training · NA · terminated
- NCT02724930 — Cooperative Pain Education and Self-management · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04318639 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Connecticut Healthcare System
- Last refreshed: 24 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04318639.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing